Rare Diseases
Latest News
Scurvy: A Diagnosis Still Relevant Today
Scurvy can cause mucosal and gastric hemorrhages, and may be linked to poor diet or bariatric surgery.
News from the FDA/CDC
Benralizumab Now FDA Approved to Treat EGPA Vasculitis
In a clinical trial, nearly 60% of participants achieved remission and 41% fully tapered off oral corticosteroids.
Latest News
Neurofibromatosis: What Affects Quality of Life Most?
“To develop effective therapeutics, meaningful clinical outcomes that are tied with improvement in QoL for persons with NF1 must be clearly...
Latest News
Second Treatment for Prurigo Nodularis Approved by FDA
Nemolizumab is currently under FDA review for treating atopic dermatitis in...
Latest News
Lipedema: Current Diagnostic and Treatment Evidence
The lack of clarity about causes of lipedema directly affects the effectiveness of diagnoses and treatments.
Latest News
Dermatofibrosarcoma Protuberans More Common In Black Patients, Analysis Finds
Researchers used the National Cancer Institute’s Surveillance, Epidemiology, and End Results (SEER) registry from 2000 through 2018 to provide a...
News from the FDA/CDC
Pyzchiva Receives FDA Approval as Third Ustekinumab Biosimilar
The biosimilar is approved for all indications of the reference medication, Stelara, and will launch in February 2025.
Guidelines
‘Therapeutic Continuums’ Guide Systemic Sclerosis Treatment in Updated EULAR Recommendations
The recommendations highlighted the use of immunosuppressive agents and antifibrotics to treat skin fibrosis and lung fibrosis, as well as changes...
From the Journals
Sex-Related Differences Found in IgG4-Related Disease Epidemiology
A recent study highlighted sex-based differences in manifestations of IgG4-related disease.
Latest News
VEXAS Syndrome: Study Highlights Cutaneous Symptoms
Affected individuals exhibit a wide range of manifestations, including cytopenia/myelodysplasia, multiorgan systemic inflammation, and cutaneous...
Conference Coverage
Autoantibodies Nonspecific to Systemic Sclerosis May Play Role in ILD Prediction
Anti-Ro/SSA antibodies predicted which patients were at most risk for ILD but not ILD progression or overall disease progression and death.